Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

David Elsea (), Lin Fan (), Adela Mihai (), Fadoua El Moustaid (), Daniel Simmons (), Matthew Monberg () and Dominic Muston ()
Additional contact information
David Elsea: Formerly of Lumanity, Inc.
Lin Fan: Formerly of Merck & Co., Inc.
Adela Mihai: AstraZeneca
Fadoua El Moustaid: Formerly of Lumanity, Inc.
Daniel Simmons: AstraZeneca
Matthew Monberg: Merck & Co., Inc.
Dominic Muston: Merck & Co., Inc.

PharmacoEconomics - Open, 2022, vol. 6, issue 6, No 13, 899-899

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-022-00372-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:6:d:10.1007_s41669-022-00372-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-022-00372-0

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().